| Revenue FY27 (Guided) | ₹700 Cr+40% Growth Target |
|---|---|
| Market Cap | ₹3,432.5 CrPharmaceuticals |
| Net Profit (Qtr) | ₹25.62 Cr114% YoY Growth |
| RSI | 74.62Overbought Zone |
Key highlights
- Revenue guidance for FY27 revised to ₹700Cr+ from the previous ₹600Cr target
- Long-term goal set to reach ₹1,500 crore revenue by FY30 with 25-30 percent annual growth
- Oncology segment currently contributes 20-25 percent of revenue with expectations to reach 30 percent
- Secured 60-70 new product registrations in the last three quarters across LATAM and MENA regions
- Planned capex of ₹185-190 crore for hormone, oncology, and biosimilar development
- EBITDA margins projected to improve to 30 percent as revenue scales toward the ₹1,000 crore mark
- Clinical trials for Erythropoietin biosimilar scheduled to commence in November 2026
Financial Performance
Kwality Pharmaceuticals reported a robust performance for the first quarter of FY27, with operating revenue reaching ₹162.35 crore, a 45.63 percent increase year-on-year. Net profit for the quarter stood at ₹25.62 crore, marking a significant growth of 114.87 percent compared to the same period last year. The operating profit margin was recorded at 25.27 percent.
Management highlighted that while gross margins shifted to 53 percent from earlier levels, the overall EBITDA margin is expected to stabilize between 26 percent and 27 percent. The company aims to optimize its working capital cycle, targeting a reduction in debtor days from 208 to approximately 165 days by the end of the fiscal year.
Management Outlook
The management expressed high confidence in achieving its long-term revenue milestone of ₹1,500 crore by FY30. This growth is underpinned by the 'first generic' strategy, where the company identifies gaps between reference products and generic entries in highly regulated markets. Kwality is expanding its operational capacity with its sixth unit, a hormone plant, scheduled for commissioning in November 2026.
This facility is expected to generate immediate revenue from the ROW markets, with potential contributions reaching ₹200 crore by FY29. Furthermore, the company anticipates a boost in margins as high-value oncology and biosimilar products begin contributing a larger share of the overall product mix.
Business Overview
Kwality Pharmaceuticals operates five distinct units specialized in biologicals, general facilities, oncology, cephalosporin, and beta-lactam. The company is transitioning toward becoming a more competitive global player by securing PIC/S and European certifications for its production lines. Currently, the oncology division accounts for about 20 percent of revenue, which is projected to rise as new registrations in the MENA and LATAM regions, specifically Mexico and Saudi Arabia, come online.
The company is also moving into complex injectables and biosimilars, with the Erythropoietin program expected to launch in both domestic and international markets by the end of 2027.
Sector Dynamics
The pharmaceutical sector is seeing a shift toward niche generic markets where regulatory barriers like COFEPRIS Mexico or Colombian approvals limit competition. Kwality is leveraging its ability to prepare 60 to 70 new product dossiers annually to gain a competitive edge. Management noted that while geopolitical disruptions previously impacted receivables in the Middle East, the situation is normalizing.
The company maintains a low dependence on Chinese APIs, sourcing 80 to 85 percent of its raw materials domestically, which insulates it from significant global supply chain shocks.
What to Watch
- Appointment of KPMG as statutory auditors by the fourth quarter of FY27 following an upcoming EGM.
- Status of clinical trial closures for the Keytruda biosimilar, aiming for the first wave of launch by 2028.
- Revenue ramp-up from Saudi Arabia and GCC countries following recent certificate approvals.
- Execution of the ₹185-190 crore capex plan focused on hormone and oncology expansions.
- Sustainable reduction in the Cash Conversion Cycle toward the guided 165-day target.
“Kwality Pharma is becoming more competitive due to the number of plants which we have in portfolio, and the number of products and the lines.”
“So we are talking about doubling our revenues before end of FY30. So we will see a year-on-year growth of 25% to 30%.”
| Share price | ₹3308.05 |
|---|---|
| Market capitalisation | ₹3,432.50 Cr |
| Revenue (annual) | ₹503.08 Cr |
| Net profit (annual) | ₹67.35 Cr |
| Revenue (latest quarter) | ₹162.35 Cr+3.33% vs previous quarter |
| Net profit (latest quarter) | ₹25.62 Cr+1.28% vs previous quarter |
| P/E (TTM) | 42.35×Sector 45.79× |
| Promoter holding | 54.86%-0.01% QoQ |
| FII holding | 3.13%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Kwality Pharmaceuticals Limited regarding the transcript of its Q1 FY27 Earnings Conference Call held on August 10, 2026. Market figures from a third-party data provider.
